InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,314.27
(
0.14%
)
US TECH 100
18,329.20
(
0.55%
)
Dow Jones
39,432.24
(
-0.60%
)
Brent Oil
81.96
(
0.52%
)
Bitcoin
67,793.52
(
-1.90%
)
Post# of 251908
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119681
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ronpopeil post# 242102

Friday, 04/15/2022 2:04:30 PM

Friday, April 15, 2022 2:04:30 PM

Post# of 251908
TGTX is now a clinical-stage autoimmune company. Due to the phase-3 failure of the Ukoniq/ublituximab combination in CLL/SLL and the withdrawal of Ukoniq from the market,* all TGTX has left is the clinical program for ublituximab in MS.

I’ve been a long-running skeptic of TGTX due to corporate-governance issues. Releasing today's news on a market holiday is par for the course.

*If TGTX hadn’t withdrawn Ukoniq voluntarily, the FDA would almost certainly have revoked Ukoniq’s accelerated approval in FL.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up